Asset
Belacabnagene Franleucel
Revenue
No revenue reported in loaded filings.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06557265 | phase1_2 | recruiting | 2024-06-13 | 2027-04-01 | Nkarta, Inc. | A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1) |
| NCT06733935 | phase1_2 | recruiting | 2024-11-04 | 2028-10-01 | Nkarta, Inc. | A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2) |
| NCT05020678 | phase1 | active_not_recruiting | 2021-08-20 | 2025-03-31 | Nkarta, Inc. | NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers |
FDA applications (0)
This company has no applications containing this asset.